Inmune Bio Files 8-K with Financial Statements
Ticker: INMB · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, sec-filing
Related Tickers: INMB
TL;DR
INMB filed an 8-K. Standard financial update, nothing major.
AI Summary
On October 28, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a specific material event. No new financial figures or significant business developments were detailed in the provided excerpt.
Why It Matters
This filing serves as a standard disclosure for Inmune Bio, Inc., providing investors with updated financial information and exhibits as required by the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- October 28, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-38793 (identifier) — Commission File Number
- 47-5205835 (identifier) — IRS Employer Identification No.
- 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432 (address) — Principal Executive Offices
- 858-964-3720 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Inmune Bio, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of October 28, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 28, 2024.
In which U.S. state is Inmune Bio, Inc. incorporated?
Inmune Bio, Inc. is incorporated in Nevada.
What is the principal executive office address for Inmune Bio, Inc.?
The principal executive office address is 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
Does this filing indicate any specific new business developments or financial results?
Based on the provided excerpt, this filing primarily concerns routine financial statements and exhibits, and does not detail specific new business developments or financial results.
Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-28 16:00:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0218711-8k_inmune.htm (8-K) — 23KB
- ea021871102ex99-1_inmune.htm (EX-99.1) — 15KB
- 0001213900-24-091170.txt ( ) — 214KB
- inmb-20241028.xsd (EX-101.SCH) — 3KB
- inmb-20241028_lab.xml (EX-101.LAB) — 33KB
- inmb-20241028_pre.xml (EX-101.PRE) — 22KB
- ea0218711-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On October 28, 2024, INmune Bio Inc. (the "Company"), issued a press release announcing that on November 7, 2024, the Company is hosting a webinar titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials." A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated October 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: October 28, 2024 By: /s/ David Moss Name: David Moss Title: Chief Financial Officer 2